Royalty Report: Diagnostic, Drugs, Cancer – Collection: 243457

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Diagnostic
  • Drugs
  • Cancer
  • Medical
  • Biotechnology
  • DNA
  • Surgical
  • Genome
  • Therapeutic
  • ribonucleic acid

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 243457

License Grant
University hereby grants to Licensee an exclusive license under the licensed patents for the terms defined to make, have made, use, sell and practice the invention in the countries where the licensed patents are effective or applications are pending, subject to rights required to be granted to the U.S. Government. Notwithstanding the preceding, University shall retain the right to make, use and practice the invention for itself for research purposes only.

University grants to Licensee a non-exclusive to make, practice and use the know-how worldwide for the term defined.

University grants to Licensee the right to grant sublicenses to third parties under terms and conditions at least equal to those contained herein provided that the terms of this agreement are included wherever applicable in such sublicenses. Licensees right to sublicense hereunder shall be exclusive to it and such sublicenses shall be coterminable with this agreement and the license granted to Licensee hereunder.

License Property
The Invention shall mean methods, processes and related reagents described in U.S. Patent Application Serial Number 271.609.

The Inventors have discovered new methods for the delineation of individual human chromosomes in metaphase and interphase cells by IN SITU suppression hybridization and have filed a patent application of like title thereon at Licensees expense (the Invention).

Licensed products or services shall mean any process, method or reagent or other product or service covered within the scope of a valid claim of the licensed patents and any product produced or manufactured using any such process, method or reagent and any service performed using any such process, method or reagent.

Field of Use
The subject invention relates to a method of detecting, identifying and/or quantitating selected individual chromsomes in mammalian mitotic or interphase cells, by means of chromosomal in situ suppression (CISS) hybridization and its use in analyzing cells for the occurrence of chromosomes, chromosome fragments, or chromosome aberrations, such as those associated with a condition or disease.
In the method of the present invention, chromosome-specific probes (DNA or RNA) are combined with a sample to be analyzed, in such a manner that an individual chromosome(s) of interest is labeled and the complex spectrum of sequences which comprise the chromosome can be detected. The probes used in the present method are of high genetic complexity and can be appropriately-selected cloned DNA or RNA fragments, used individually or in pools, or chromosome library DNA.

IPSCIO Record ID: 26962

License Grant
The University hereby grants to Licensee exclusive, worldwide licenses under Regents’ Patent Rights within the Field of Interest to make, have made, use, sell, distribute, and lease machines, articles of manufacture, and compositions-of-matter and to perform processes and have others perform processes.
License Property
The Invention has utility for the detection of chromosome abnormalities.

Patent Rights shall mean all U.S. and foreign patents and patent applications related to Pending U.S. Patent Application Serial No. 819,314 & 6-937,793 entitled Method and Compositions for Chromosome-Specific Staining ;.Pending U.S. Patent Application Serial No. 6-934,188 entitled Method of Preparing and Applying Single Stranded DNA Probes to Double Stranded Target DNAs; Any U.S. Patent Application based on subject matter described in UC Case Number 87-095-1 (renumbered UC Case Number 85-157-4) entitled Method for Determining Aneuploidy in Fetal Cells from Maternal Blood Samples.

Field of Use
'Field of Interest' shall mean relating to analytical, research, and diagnostic applications of technology based on chromosomal staining, marking, and labeling.  Field of Interest shall specifically exclude therapies and treatments derived from analytical, research, and diagnostic applications.

IPSCIO Record ID: 159305

License Grant
The Great Britain University grants to Licensee and its Affiliates a worldwide exclusive license under its Patent Rights, Technology, and Tangible Technical Materials to make, have made, import, use, offer to sell, or sell Licensed Subject Matter during the Term of this Agreement.
License Property
Licensed Subject Matter shall mean Licensed Patent Product, Patent Rights, Technology, and Tangible Technical Materials for in-vitro diagnostic assays, using labeled nucleic acid probes.

UK Patent Application Number 9704054.7 entitled 'Chromosome-specific Paint Probes'

The University owns Technology and Tangible Technical Materials related to Assays to Detect and Analyze Chromosomal Aberrations in various species using labeled DNA from a related species as a set of probes and, the United Kingdom patent for Chromosome-specific Paint Probes.

Based upon a novel method developed by scientists at the University, the Company's RxFISH(TM) assay develops a unique fluorescent color banding pattern for human chromosomes that is then analyzed by the CytoVision software.

Field of Use
The field is in-vitro diagnostic assays, using labeled nucleic acid probes.  The Licensee is in the business of automated clinical analysis systems used by cytogenetic laboratories for prenatal and other genetic testing applications.

IPSCIO Record ID: 246729

License Grant
University and Licensee agree as follows

University hereby consents to the assignment of the License to Licensee by Genzyme Genetics, effective February 2, 2000.

Licensee shall obtain from the University of California an abandonment of the University of Californias opposition to the European Ward patent, and shall deliver the University of Californias written abandonment of the opposition to University by no later than February 4, 2000. University shall be responsible for filing the abandonment in the European Patent Office.

In consideration of Universitys consent to this assignment and execution of this Agreement, Licensee agrees to carry out a royalty-bearing sublicensing program for the Ward Patents and to hold reviews at six month intervals with University on its sublicensing activities under the License, unless and until both parties agree that such reviews are no longer necessary.

In consideration of Licensee obtaining the abandonment of the European opposition and the amendment to the License set out herein, University releases Licensee of any claim for breach of the License that arose before the Effective Date, including any claim for sales of products before the Effective Date by Licensee, and agrees that all obligations of the Licensee under the License are current as of the Effective Date.

Licensee acknowledges that the License grants no rights under U.S. Patent Nos. 6,007,994 and 5,759,781 (Ward mFISH patents) or any patents deriving from the U.S. patent application No. 08/577,622 filed on December 22, 1995.

University and Licensee agree to the amend the Earned Royalty Rate and Sublicense Rate.

No other changes are made, and as amended the Exclusive License continues in full force and effect.

License Property
The Invention shall mean methods, processes and related reagents described in U.S. Patent Application Serial Number 271.609.

Licensed Products or Services shall mean any process, method or reagent or other product or service covered within the scope of a valid claim of the Licensed Patents and any product produced or manufactured using any such process, method or reagent and any service performed using any such process, method or reagent.

Field of Use
This agreement pertains to the healthcare industry relating to drugs for the delineation of individual human chromosomes in metaphase and interphase cells by IN SITU suppression hybridization.

IPSCIO Record ID: 27510

License Grant
The Licensor gave an exclusively license to the Company of patent titled One-Step In Situ Hybridization Assay.
License Property
The patent applications owned or co-owned by the Company either seek to cover improvements in reagents and methods of performing an in situ hybridization process or seek to cover methods of identifying and isolating fetal cells for prenatal diagnosis by in situ hybridization.

Among its claims is one that recites a method for assaying nucleic acids in a sample of cells having substantially intact membranes. The claimed method consists essentially of the steps of contacting the sample with a medium comprising a fixative agent, a denaturing agent, a hybrid stabilizing agent, a buffering agent, a membrane pore-forming agent and at least one nucleic acid probe. The contacting is under hybridizing conditions. The sample is incubated with the medium in the presence of at least one detectable label, and duplex formation is detected by means of the label, wherein the method is capable of detecting as few as one to five copies of a target nucleic acid per cell. Another claim applies to the foregoing process, in which the detection is carried out by flow cytometry. The patent also contains claims for kits.

IPSCIO Record ID: 146089

License Grant
Licensor grants a nonexclusive immunity from suit under PCR Technology solely to perform Licensed Services.

Licensor grants to Licensee the right to credit the Licensor as the source of PCR Technology in Licensees promotional materials and any other materials intended for distribution.

License Property
PCR or polymerise chain reaction is a nucleic acid amplification process.

Licensed Services means the performance of an IN VITRO diagnostic procedure utilizing PCR Technology to detect the presence, absence or quantity of a nucleic acid sequence associated with a human disease or condition within the Licensed field.

The Diagnostic product shall mean an assemblage of reagents, including but not limited to reagents packaged in the form of a kit, useful in performing a Licensed Service.

The licensed credit is 'This test is performed pursuant to a license agreement with Licensor.'

Field of Use
Licensor has expertise in validating, documenting and performing sophisticated diagnostic procedures.  The field is that of human IN VITRO diagnostics solely for the detection of genetic diseases, genetic predisposition to disease, agents associated with infectious diseases, cancer; and for tissue transplant typing, including testing performed on animal tissue intended for use in xenotransplantation; Parentage determination; disease management; and clinical trials.

IPSCIO Record ID: 6970

License Grant
Licensor hereby grants to Licensee and its Affiliates a royalty-bearing, exclusive (even as to Licensor, except for the retained rights described in Section 2.1(b) below), transferable (solely in accordance with Section 11.1), sublicensable (solely in accordance with Section 2.2) license or sublicense, as the case may be, under its rights in the Patent Rights and Technology, to develop, make, have made, use, sell, have sold, offer to sell, import, export, reproduce, distribute, perform and display, and otherwise dispose of Licensed Products, and to develop and perform Licensed Services, and to use and practice in products and services any process, art or method, included in the Licensor Technology, in the Territory in the Field of Use. This Agreement is subject to the relevant terms of the Brandeis License applicable to sublicensees as such terms have been incorporated herein, as the Brandeis License may be amended from time to time, provided, that (i) as provided in Section 2.1(c) below, the Brandeis License may not be amended in a manner that materially and adversely affects the rights and benefits extended to Licensee hereunder without the prior written consent of Licensee, and (ii) in the event of any inconsistency between the Brandeis License and Section 2.1(c) hereof, Section 2.1(c) hereof shall govern.
License Property
Patent Rights
U.S. Patents – 5,480,772; 5,651,992; 5,773,217; 6,245,567; 6,753,457; 6,878,546.
U.S. Patent Applications – 10/798,061; 10/969,646.
Foreign Patent Applications – WO9418344; EP154931; EP0686202; CA2155309.
Field of Use
Field of Use means
(a)  non-human cells, embryos, organs, organisms;
(b)  any of (a) above as cloned, transgenic, or cloned transgenic forms;
(c)  any protein products and other biological molecules produced by, or prepared from, (a) and (b) above;
(d)  any methods, technologies, or processes for the creation of (a) through (c) above;
(e)  therapeutic and diagnostics (including products, devices, or processes) of (a) through (d) above;
(f)  cloned, transgenic, or cloned transgenic human cells, tissues and organs not derived by Human Cloning (as defined below).

The Field of Use shall under no circumstances include
(i)  the use of Human Reproductive Cells (Human Reproductive Cells are defined herein as human meiotic or post-meiotic germ cells, human gametes, human fertilized eggs, or human pre-implantation embryos) for any purpose;
(ii)  Human Cloning (wherein Human Cloning is defined as any action combining a human egg or any part thereof, with the nucleus or any nuclear material from any human cell);
(iii)  human embryos, cloned embryos, human tissue derived by Human Cloning; or
(iv)  transgenic human embryos, transgenic cloned human embryos, transgenic human cells, or transgenic human tissues derived by Human Cloning.

IPSCIO Record ID: 144892

License Grant
Licensor grants a non-exclusive, non-transferable license under Patent Rights to practice Licensed Methods in the Field within Licensors laboratories and to make, have made, use, and export Licensed Products solely for use byLicensee, in the practice of Licensed Methods in the Field. License grant shall not include the right to sell Licensed Product and/or Licensed Method to third parties.
License Property
Licensor owns certain patents covering compositions and processes for detecting ribosomal nucleic acid subsequences belonging to groups of non-viral organisms.

The patents refer to Methods for Detection. Identification and Quantification of NonViral Organisms.

Field of Use
The Field shall mean the performance of human, clinical diagnostic Assays and Assay Series using one or more nucleic acid probes, including peptide nucleic acid probes and probes with modified sugar or phosphate groups, which are designed to detect whether or not bacteria are present in a sample by hybridizing to one or more pan-bacterial regions of ribosomal nucleic acid, whether ribosomal RNA or ribosomal DNA, in order to determine the presence or amount of bacteria which may be present in a human sample. 'Field' shall not include Assays and Assay Series only to detect, quantitate or identify any group of organisms less than or different than that encompassing all bacteria.

IPSCIO Record ID: 233466

License Grant
This Agreement is to allow the Licensee to exclusively develop and market products based on the Licensed Technology within the Exclusive Field.

Licensor hereby grants to Licensee a Semi-Exclusive, royalty-bearing license, including the right to grant sublicenses, under the Licensed Patent Rights and under all of Licensor’s right, title and interest in and to the Licensed Technology and Improvements, to make, have made, use, have used, sell, offer for sale, have sold, import, and have imported Licensed Products and to perform and have performed Licensed Services in the Territory.

Semi-Exclusive shall mean that the license granted herein to Licensee shall be exclusive, even as pertaining to Licensor, within the Field, provided, however, that Licensor hereby retains the right to perform activities within the Co-Exclusive Field without the right to grant further licenses or sublicenses within the Co-Exclusive Field.

License Property
The Licensed Technology shall mean and include all Technology, whether or not patentable, that is useful for the performance of Sequencing by Synthesis (SBS) within the Field and that is Controlled by Licensor as of the Effective Date. Licensed Technology specifically does not include any biomarkers (content) Licensor has identified utilizing SBS and other technologies for generation of sequence information, when not used in association with SBS, such as capillary electrophoresis, mass spectrometry and sequencing by hybridization.

Sequencing by Synthesis or SBS shall mean Licensors proprietary process for determining the sequence of genetic material by synthesizing from a template derived from such material.

Licensors Kit shall mean all reagents, equipment, components, kits and instructions for preparation and operation that are necessary and sufficient for Licensee to sequence a sample.

Hardware Products shall mean Licensed Products that consist of hardware or instruments used in SBS, but excluding any such hardware or instruments that are used for Sample Preparation or instruments used for assemblies or analysis of sequence information, for example computer processing units.

Licensed Product shall mean any product, the manufacture, use, sale of which would, absent the license granted to Licensee hereunder, infringe any Valid Claim included in the Licensed Patent Rights.

Licensed Services shall mean any service performed by Licensee for a Third Party, the performance of which would, absent the license granted to Licensee hereunder, infringe any Valid Claim included in the Licensed Patent Rights.

Reagent Products shall mean Licensed Products that consist of reagents that are used to perform SBS excluding any kits, reagents or components that are used for Sample Preparation and excluding any hardware or instruments.

Field of Use
Co-exclusive field shall mean sequencing applications performing between 10,000 to 50,000 different DNA sequencing reactions in one process cycle, including but not limited to, with respect to any or all organisms and for whatever purpose or purposes, a) sequencing all or essentially all, of a genome, genomic region, or chromosome based on sequencing, b) expression profiling based on cDNA/mRNA sequencing, c) repetitive sequencing of genomic regions or specific cDNA, and, d) performing SNP analyses of whole genomes or between 10000 to 50000 where the license is non-exclusive under this agreement.

Exclusive Field shall mean sequencing applications performing between 10000 to 50000 different DNA sequencing in one  process cycle, including but not limited to, with respect to any or all organisms and for whatever purpose or purposes, a) sequencing all or essentially all, of a genome, genomic region, or chromosome based on sequencing, b) expression profiling based on cDNA/mRNA sequencing, c) repetitive sequencing of genomic regions or specific cDNA, and, d) performing SNP analyses of whole genomes or more than 50000 in one process cycle.

Field shall mean sequencing applications performing more than 10000 different DNA sequencing in one  process cycle, including but not limited to, with respect to any or all organisms and for whatever purpose or purposes, a) sequencing all or essentially all, of a genome, genomic region, or chromosome based on sequencing, b) expression profiling based on cDNA/mRNA sequencing, c) repetitive sequencing of genomic regions or specific cDNA, and, d) performing SNP analyses of whole genomes or more than 10000 in one process cycle.

IPSCIO Record ID: 383582

License Grant
In the original agreement, Licensor granted
— For the Layton and Stanford Patent Rights a nonexclusive, non-transferrable, limited sub-licensable, world-wide license under the Layton Patent Rights and the Stanford Patent Rights to practice and use the subject matter within the Layton Patent Rights and the Stanford Patent Rights in the Licensee Database Field of Use, Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use.
— For the Montefiore Patent Rights, a non-transferrable, limited sub-licensable, world-wide license under the Montefiore Patent Rights to practice and use the subject matter within the Montefiore Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use.
— For the Cancer Marker Patent Rights, Licensor grants a non-transferrable, limited sub-licensable, world-wide license under the Cancer Marker Patent Rights to practice and use the subject matter within the Cancer Marker Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use, only with respect to cancer.
— For the Database Patent Rights and Seilhamer/Scott Patent Rights, Licensor grants a nonexclusive, non-transferable, non-sublicensable , world-wide license under the Database Patent Rights and Seilhamer/Scott Patent Rights to practice and use the subject matter within the Database Patent Rights and the Seilhamer/Scott Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use, and the Personalized Research Field of Use.
— For the Sublicenses, Licensee shall have the right to grant sublicenses to third parties under such Patent Rights on a Product-by-Product basis to make, use, import, sell, and offer for sale Products developed by Licensee or its Affiliates.
— For the Co-Exclusive Licenses in the Homebrew and Diagnostic Fields of Use, Co-Exclusive shall mean that each Party has the right to exercise all of the rights under the Patent Rights in question in the field of use for which the parties have co-exclusive rights, without obligation to the other except to the extent provided in this Agreement, and neither Party alone has the right to grant sublicenses to third parties under such Patent Rights without express written consent of the other Party.
License Property
Cancer Marker Patent Rights shall mean all Valid Claims listed in any of the following patents and patent applications, to the extent that they are owned by Licensor with the right to license under this Agreement, and to the extent that they claim the composition of matter or use of any nucleic acids or proteins as markers or diagnostics for cancer.

The patents include
— Processes for Genetic Manipulations Using Promoters;
— Method for Detecting Pathological Conditions;
— Comparative Gene Transcript Analysis; and,
— Methods for Fabricating Micro Arrays of Biological Samples.

Field of Use
Licensee licenses various classes of patents from Licensor pertaining to the manipulation of genes, the detection of pathological conditions, comparative gene analysis, methods for fabricating tests of biological samples and the use of proteins as markers for cancers.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.